Alice Mattsson

The problem 10 million women/couples are trying to conceive annually in Europe & the US with 1,6M of these struggling to get pregnant. On average, 18 pregnancy tests and 50 ovulation tests are consumed per successful pregnancy. Available solutions in the mid-range space offer questionable usability and accuracy, with no guidance or support. The Solution Developed by a team with more than 80 years of combined experience in the fertility market, ova&me offers an advanced all-in-one solution for those trying to conceive. The single device tracks both ovulation and pregnancy while factoring in personal hormone levels to optimise conception chances. When connected to their smartphone app, users are offered precise hormone readings, AI-powered analysis, and accredited guidance through supportive and engaging content. Milestones achieved \- Raised €750k in non-dilutive funding and in a convertible from Novo Nordisk Foundation via Bio Innovation Institute \- Ordered the first samples of the product and de-risked scale-up manufacturing \- Performed 2 usability studies, with 90% of 218 women being interested in the solution over existing products \- Secured exclusive access to a technology that outperforms Clearblue and First Response (market leaders) against a 2% royalty fee on net sales \- Offer a stellar business model with sound price-points and gross margins, based on the razor & blades model \- Have a clear, de-risked regulatory strategy in place Upcoming milestones In Q1 2027, the team is launching their solution onto the US market, after securing 510(k) approval, for which they are raising $1.5M. Built as a scalable platform, the technology is designed to support additional tests over time. ova&me's next-generation product is expected to focus on quantitative at-home tracking of hCG (the pregnancy hormone), enabling patients and clinicians to monitor pregnancy progression remotely. This approach addresses a significant unmet need by reducing the need for frequent in-clinic blood draws, which are currently required every other day for IVF patients and women with high-risk pregnancies.